瑞信-美股-生物科技行业-美国生物科技：与Galapagos的通话纪要-2020.3.10-23页.pdf

10 March 2020 Equity Research Americas | United States U.S. Biotechnology Call Transcript following Virtual Fireside Chat with Galapagos Biotechnology | Comment We hosted Galapagos’ CFO COO Bart Filius to discuss filgotinib as well as other pipeline Research Analysts assets including GLPG1972 for OA and GLPG1690 for IPF. We also discussed the latest developments for the Toledo program and expectations for the company’s discovery Evan Seigerman platform for the balance of 2020. 212 325 4463 evan.seigerman@ We have included the full transcript of the call in this document. Matthew Terwelp, MD A replay of the call is available: (855) 859-2056 // (404) 537-3406; ID: 2166399 212 325 3493 matthew.terwelp@ DISCLOSURE APPENDIX AT THE BACK OF THIS REPORT CONTAINS IMPORTANT DISCLOSURES, ANALYST CERTIFICATIONS, LEGAL ENTITY DISCLOSURE AND THE STATUS OF NON-US ANALYSTS. US Disclosure: Credit Suisse does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. 10 March 2020 CREDIT SUISSE SECURITIES, LLC Moderator: Evan Seigerman Ma